Key facts
- This page summarizes Pershing Edward's Form 4 filing for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 28 Jul 2023, 15:36.
Pershing Edward - 28 Jul 2023 Form 4 Insider Report for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
- Reporting relationship
- Director
- Issuer ticker
- PVCT
- Reported as of
- 28 Jul 2023
- Net transaction value
- -$81,067
- SEC form
- 4
- Accepted by SEC
- 28 Jul 2023, 15:36:06 UTC
- Prior SEC filing
- 26 Jul 2023
- Next SEC filing
- 04 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Edward Pershing
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Pershing Edward filed Form 4 for PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) on 28 Jul 2023.
Change
- Previous filing in this sequence was filed on 26 Jul 2023.
- Current net transaction value: -$81,067.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PVCT
transaction
Derivative
8% Unsecured Convertible Promissory Note
Options Exercise
- Transaction value
- $81,067
- Shares
- Change %
- Price
- Shares after
- $100,000
- Date
- 28 Jul 2023
- Ownership
- Direct
- Underlying class
- Series D-1 Convertible Preferred Stock
- Underlying amount
- 28,326
- Exercise price
- $2.86
- Footnotes
- F1, F2
PVCT
transaction
Derivative
Series D-1 Convertible Preferred Stock
Options Exercise
- Transaction value
- $0
- Shares
- +28,326
- Change %
- +5.3%
- Price
- $0.000000
- Shares after
- 563,891
- Date
- 28 Jul 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 283,260
- Exercise price
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The Reporting Person could have elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note due 2023 (the "Note") as follows: (i) the Note is convertible into shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Preferred Stock") at a price per share equal to $2.862; (ii) in the event the Issuer conducts a qualified equity financing in the aggregate amount of $20 million, the Note is convertible into the shares of capital stock being issued by the Issuer in such qualified equity financing at the price per share being paid by the investors in such qualified equity financing; and (iii) in the event the Issuer conducts a qualified debt financing with more favorable terms than the Note in the aggregate amount of $20 million, the Note may be exchanged for the debt instrument being issued by the Issuer in such qualified debt financing.
Footnote F2
On July 28, 2023, the Note was converted into 28,326 shares of Series D-1 Preferred Stock.
Footnote F3
Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
Footnote F4
The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.